Nanotechnology in Drug Delivery Market Size, Definition, Opportunities with Strategic Growth and Top Key Players Analysis and Forecasts to 2027
Research report presented by UnivDatos, Emphasis on
Technology (Nanoparticles, Liposomes, Nanocrystals, Micelles, Others),
Application (Oncology, Cardiovascular/Physiology, Anti-inflammatory/Immunology,
Neurology, Anti-infective, Others) and Geographical analysis (key regions and
countries).
As per the research report, Global Nanotechnology in Drug
Delivery Market is expected to reach the
market valuation of US$ 182.3 billion by 2027 expanding at a reasonable CAGR of
19.9% during the forecast period (2021-2027) from US$ 44 billion in 2019. To enhance the uptake of poorly soluble medications, drug targeting to
a specific location, and drug bioavailability, nanotechnology is used in
selective drug delivery at the site of disease.
Through
modifying the properties of materials such as polymers and building
nanostructures, nanotechnology offers superior drug delivery mechanisms for
improved disease management and care. Nanostructures used as drug delivery
systems have a number of benefits that set them apart from traditional delivery
systems. In recent years, nanoparticles have
been important players in scientific medicine, with uses ranging from contrast
agents in medical imaging to gene delivery carriers in human cells. Researchers
are focused on how to use nanoparticles to improve drug efficacy by gaining a
better understanding of how nanoparticles bind with cells and the best toxicity
or concentration. Healthcare R&D is seeing an uptick in spending on
nanoscale materials and applications.
For complete research, request for
Sample of the report browse through – https://univdatos.com/request_form/form/355
In
recent years, a growing number of nanotherapeutic drugs have been
commercialised or advanced to the clinical level. NP-based drug delivery
mechanisms are consistent with improved pharmacokinetics, biocompatibility,
tumour targeting, and durability as compared to generic medications, while also
minimising systemic toxicity and resolving drug resistance. Over 20% of the
therapeutic nanoparticles in clinics or under clinical evaluation for oncology
applications have been created. The majority of FDA-approved therapeutic
nanoparticles are currently being developed for re-formulation of
chemotherapeutic drug combinations containing polymeric nanoparticles. CVDs
murder 17.9 million people a year, according to the WHO, accounting for 31% of
all deaths worldwide. The use of nanoparticle-based formulations in the
treatment of cardiovascular disorders is mainly dependent on targeted delivery
and increased bioavailability for vascular restenosis. According to the
National Institutes of Health, up to 23.5 million Americans (more than 7% of
the population) have an autoimmune disease, and the figure is growing. One of
the major factors causing this increase is the increasing incidence of cancer
and chronic diseases.
COVID-19 Impact
The
current influence of COVID-19 on public health is immense, but the global
impact on the environment, workers, and businesses will be important as well.
This global emergency necessitates a research and technology response to the
COVID-19 pandemic, with nanotechnology expected to be tested for advanced
solutions during the outbreak. A research by Leuschner et al. points in the
direction of using nanotechnology to monitor the cytokine storm, which is one
of COVID-19's few clinical problems. Nanoparticles play an important role in
disease pathogenesis at various levels, including their ability to prevent
initial attachment and membrane fusion during viral entry and infected cell
protein fusion.
For a detailed analysis of the applications in the Nanotechnology
in Drug Delivery Market browse through – https://univdatos.com/report/global-nanotechnology-in-drug-delivery-market-current-analysis-and-forecast-2020-2027
Insights Presented in the Report
“Amongst application, oncology is anticipated to dominate the market
during the analyzed period”
The market is
further divided into oncology, cardiovascular/physiology, anti-inflammatory/
immunology, neurology, anti-infective, and others depending on use. Because of
the advantages of nanoparticle (NP)-based drug delivery systems in cancer
therapy, such as strong pharmacokinetics, accurate targeting of tumour cells,
reduction of side effects, and drug tolerance, oncology accounted for the
highest industry revenue share of 36% in 2019 and is projected to remain
dominant throughout the studied era. The anti-inflammatory/immunology section,
on the other hand, is expected to rise at the fastest CAGR during the forecast
era.
“Amongst technology, nanoparticles segment holds the major share”
The
market is divided into nanoparticles, liposomes, nanocrystals, micelles, and
other technology types. Due to greater biocompatibility, non-immunogenicity,
non-toxicity, and biodegradability relative to traditional approaches, the
nanoparticles segment dominated the market in 2019 with a share of 27.2 percent
and is projected to continue its dominance throughout the forecast era.
“North America signifies one of the largest markets of Nanotechnology in Drug Delivery Market”
A
systematic research was performed for various regions around the globe,
including North America (United States, Canada, and the Rest of North America),
Europe
(Germany, France, Italy, Spain, United Kingdom and Rest of Europe),
Asia-Pacific (China, Japan, Australia, South Korea, India, and the Rest of
APAC), and the Rest of the World, to gain a better understanding of the market
dynamics of the Nanotechnology in Drug Delivery Market. Because of the rising
prevalence of cancer, the availability of high disposable income, and an
increase in support for R&D activities associated with Nanotechnology in
Drug Delivery, North America dominated the market and delivered sales of US$
18.9 billion in 2019. Cancer, for example, is the leading cause of death in
Canada and the second-leading cause in the United States, after heart disease.
In 2018, it was projected that almost 1.9 million new cancer cases and 693,000
cancer deaths occurred in North America.
Customization Options:
The Nanotechnology in Drug Delivery Market can further
be customized as per the requirement or any other market segment. Besides this,
UMI understands that you may have your own business needs, hence feel free to
connect with us to get a report that completely suits your requirements.
Table of Contents
1 Market
Introduction
2 Research Methodology
or Assumption
3 Industry
Performance
4 Executive
Summary
5 Few Top
Start-Ups Under Nanotechnology in Drug Delivery Sector
6 Nanotechnology
in Drug Delivery Amid COVID-19
7 Global
Nanotechnology in Drug Delivery Market by Revenue
8 Market
Insights by Technology
9 Market
Insights by Application
10 Market
Insights by Region
11 Nanotechnology
in Drug Delivery Market Dynamics
12 Legal &
Regulatory Framework
13 Demand and
Supply Side Analysis
14 Value Chain
Analysis
15 Nanotechnology
in Drug Delivery Market Opportunities
16 Nanotechnology
in Drug Delivery Market Trends
17 Competitive
Scenario
18 Company
Profiled - Camarus AB, Nanobiotix, NanoCarrier Co., Ltd., Selecta
Biosciences, Starpharma Holdings Limited, Taiwan Liposome Co., Pfizer,
Novartis, Merck & Co.
19 Disclaimer
About Us:
UnivDatos
Market Insights (UMI), is a passionate market research firm and a subsidiary of
Universal Data Solutions. Rigorous secondary and primary research on the market
is our USP, hence information presented in our reports is based on facts and
realistic assumptions. We have worked with 200+ global clients, including some
of the fortune 500 companies. Our clientele praises us for quality of insights,
In-depth analysis, custom research abilities and detailed market segmentation.
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home